Claes Lindahl

Claes Lindahl is the founder and CEO of Intellego Technologies, a company that develops patented dosimeter technology for detecting radiation and substances. Claes has been with the company since 2011 and is active in multiple sectors including consumer products, production industry, and medical/hospital. In addition, Lindahl has served as the CEO of Tendera AB, a company that develops disposable tests for periodontal disease diagnosis and treatment. Claes was the Managing Director of Edo Biotech, a biotechnology company based in Gothenburg, and worked as a Project Manager at GU Holding, a company affiliated with the University of Gothenburg. Lindahl has also worked as a Business Developer at NEUROSURGIC.com and Traccine Pharmaceuticals, and as a Market Researcher at Imego AB.

Claes Lindahl pursued their education in a chronological manner. Claes began their studies at Linköping University in 2004, where they focused on bioengineering and completed their studies in 2008. From 2006 to 2008, they also engaged in business and economics coursework at the same university. Subsequently, Claes attended Chalmers University of Technology from 2008 to 2010, where they specialized in life science and entrepreneurship.